• $26.7M
    Market Cap
  • -80.00%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
17,000
N/A
N/A
N/A
N/A
N/A
0
N/A
Cost of Revenue
70,000
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
-53,000
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
163,000
-87.67%
1.3M
-21.12%
1.7M
N/A
N/A
N/A
Research and Development Expense
-1.1M
-90.29%
-11.7M
+93.95%
-6.0M
+36.48%
-4.4M
+54.62%
Depreciation and Amortization Expense
759,000
+4,643.75%
16,000
+6.67%
15,000
0.00%
15,000
+114.29%
Total Operating Expenses
3.0M
+1.45%
3.0M
-16.37%
3.5M
-20.19%
4.4M
+2.28%
Operating Profit
-5.1M
-65.09%
-14.7M
+53.10%
-9.6M
+8.06%
-8.9M
+23.04%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
160,000
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
0
+100.00%
Interest Income and Expense and Net
0
N/A
0
N/A
0
-100.00%
160,000
+159.04%
Total Nonoperating Income and Expense
108,000
+16.13%
93,000
-62.50%
248,000
+188.37%
86,000
+368.75%
Income before Taxes
-5.0M
-65.61%
-14.6M
+56.17%
-9.3M
+6.30%
-8.8M
+21.31%
Income Taxes
8,000
0.00%
8,000
0.00%
8,000
-11.11%
9,000
+50.00%
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-5.0M
-65.57%
-14.6M
+56.12%
-9.3M
+6.28%
-8.8M
+21.34%
Net Income from Continuing Operations Applicable to Common
-5.0M
-65.61%
-14.6M
+56.17%
-9.3M
+6.30%
-8.8M
+21.31%
Basic EPS and Net Income
-7.47
-76.77%
-32.16
+350.42%
-7.14
+770.73%
-0.82
+10.81%
Diluted EPS and Net Income
-7.47
-76.77%
-32.16
+350.42%
-7.14
+770.73%
-0.82
+10.81%
Basic Weighted Average Shares
647,973
+42.87%
453,544
-65.35%
1.3M
-87.72%
10.7M
+8.65%
Diluted Weighted Average Shares
647,973
+42.87%
453,544
-65.35%
1.3M
-87.72%
10.7M
+8.65%
Balance Sheet
Cash and Cash Equivalents
3.1M
-26.66%
4.3M
-46.91%
8.0M
+95.95%
4.1M
-75.23%
Short-Term Investments
N/A
N/A
N/A
N/A
0
-100.00%
6.1M
N/A
Cash and Cash Equivalents and Short-Term Investments
3.1M
-26.66%
4.3M
-46.91%
8.0M
-21.17%
10.2M
-38.44%
Total Current Assets
4.4M
-1.74%
4.4M
-54.81%
9.8M
-20.23%
12.3M
-35.42%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
30,000
-14.29%
35,000
-7.89%
38,000
-13.64%
44,000
-16.98%
Total Long-Term Assets
30,000
-14.29%
35,000
-7.89%
38,000
-13.64%
44,000
-16.98%
Total Assets
12.0M
+165.15%
4.5M
-54.43%
9.9M
-19.45%
12.3M
-35.36%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
2.4M
-0.04%
2.4M
+1.33%
2.4M
+126.50%
1.1M
+40.55%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
4.4M
0.00%
Total Long-Term Liabilities
267,000
+3.09%
259,000
-7.83%
281,000
+15.64%
243,000
+3.85%
Total Liabilities
2.7M
+0.26%
2.7M
+0.37%
2.7M
+105.89%
1.3M
+31.89%
Retained Earnings
-61.3M
+8.57%
-56.5M
+34.85%
-41.9M
+28.73%
-32.5M
+37.05%
Total Stockholders Equity
8.5M
+368.37%
1.8M
-74.80%
7.2M
-34.32%
11.0M
-39.05%
Total Shares Outstanding
830,613
-43.55%
1.5M
-14.87%
1.7M
-83.75%
10.6M
+1.45%
Cash Flow
Cash from Operating Activities
-4.0M
-68.66%
-12.6M
+88.97%
-6.7M
+3.41%
-6.5M
-1.43%
Capital Expenditures
2,000
-84.62%
13,000
+44.44%
9,000
+50.00%
6,000
-88.00%
Cash from Investing Activities
-982,000
+7,453.85%
-13,000
-100.22%
6.0M
+199.75%
-6.0M
+11,912.00%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
3.8M
-56.92%
8.9M
+92.01%
4.6M
N/A
0
-100.00%
Financials Ratio
Gross Margin
-311.76%
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
-30,129.41%
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-60.79%
-69.88%
-201.84%
+140.40%
-83.96%
+49.93%
-56.00%
+42.48%
Return on Equity
-96.88%
-69.90%
-321.92%
+214.55%
-102.34%
+69.39%
-60.42%
+44.68%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
1.78
-1.70%
1.81
-55.40%
4.07
-64.78%
11.55
-54.05%
Cash Ratio
1.28
-26.63%
1.74
-47.61%
3.33
-13.49%
3.85
-82.38%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow